FDA.reportPublic FDA data

ocrelizumab-ocsq 920 MG / hyaluronidase-ocsq 23,000 UNT per 23 ML Injection

RxCUI
2693458
RxNorm name
ocrelizumab-ocsq 920 MG / hyaluronidase-ocsq 23,000 UNT per 23 ML Injection
Display name
ocrelizumab-ocsq 920 MG / hyaluronidase-ocsq 23,000 UNT per 23 ML Injection
Full name
ocrelizumab-ocsq 920 MG / hyaluronidase-ocsq 23,000 UNT per 23 ML Injection
Term type
SY
Status
DailyMed mapping
Updated
2026-06-04 23:39:16

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLAProprietary nameProper nameLicense typeStatusLatest source
761371Ocrevus Zunovoocrelizumab and hyaluronidase-ocsq351(a)Rx2026-08-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Ocrevus ZunovoOCRELIZUMAB AND HYALURONIDASEGenentech, Inc.b216af61-99d0-42a3-afc2-b5bf86df1ec02026-08-17Warnings, Adverse reactionsExact identifier
rxcui: 2693458

DailyMed RxNorm Mappings#

unique DailyMed labels mapped to this RxNorm concept page 1 of 1 · 1 matching rows.

Set ID, RxNorm mappings, Terms table
Set IDRxNorm mappingsTermsSPL versionLabelEffective
b216af61-99d0-42a3-afc2-b5bf86df1ec0ocrelizumab-ocsq 920 MG / hyaluronidase-ocsq 23,000 UNT in 23 ML Injection [PSN] · 23 ML hyaluronidase-ocsq 1000 UNT/ML / ocrelizumab-ocsq 40 MG/ML Injection [SCD] · ocrelizumab-hyaluronidase-ocsq 920 MG / 23,000 UNT per 23 ML Injection [SY] · ocrelizumab-ocsq 920 MG / hyaluronidase-ocsq 23,000 UNT per 23 ML Injection [SY]49These highlights do not include all the information needed to use OCREVUS ZUNOVO safely and effectively. See full prescribing information for OCREVUS ZUNOVO. OCREVUS ZUNOVO ® (ocrelizumab and hyaluronidase-ocsq) injection, for subcutaneous use Initial U.S. Approval: 202420260427